文献速递胸部肿瘤

2024年国际肺癌研究协会全球生物标志物检测调查

The 2024 International Association for the Study of Lung Cancer Global Survey on Biomarker Testing.
PubMed 文献 · J Thorac Oncol · 2025-07-22

国际肺癌研究协会2024年全球调查覆盖90国1677名受访者,发现98.3%认为生物标志物检测显著影响结局,但仅63.4%和29.4%认为晚期和早期肺癌全面检测非常重要;67%估计本国过半患者接受检测,较2018年39%上升(P<0.0001);43%有时或常在结果回报前治疗,主要障碍为费用、时间、样本质量、可及性和认知。

要点

  • 98.3%受访者认为生物标志物检测显著影响结局,91.2%清楚谁应接受检测。
  • 仅63.4%和29.4%认为晚期和早期肺癌全面检测非常重要。
  • 67%估计本国过半患者接受检测,较2018年39%上升(P<0.0001)。

核心结论

  • 与2018年相比,受访者对检测率的感知有所改善,但持续存在重大障碍。
  • 未来倡议将利用这些数据针对认知、可及性、流程和政策举措,以改善全球全面检测。

研究设计与样本

  • 国际肺癌研究协会召集全球多学科委员会制定调查,采用混合方法框架,定性焦点小组和深度访谈为定量调查提供信息。
  • 调查以六种语言提供,共收到来自90个国家、14个学科的1677份回复。

主要发现

  • 98.3%受访者认为生物标志物检测显著影响结局,91.2%清楚谁应接受检测。
  • 仅63.4%和29.4%受访者认为晚期和早期肺癌全面生物标志物检测非常重要。
  • 67%受访者估计本国超过一半肺癌患者接受生物标志物检测,较2018年调查的39%上升(P<0.0001)。
  • 43%受访者有时或常在获得生物标志物结果前治疗患者。
  • 排名最高的障碍为费用27.2%、时间13.9%、样本质量13.8%、可及性12.8%、认知8.0%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Biomarker status is vital to inform optimal care for individuals with lung cancer, yet implementation of testing has been suboptimal due to cost, lack of quality and standards, access, awareness, and long turnaround times. Recent therapeutic advances in late- and early-stage lung cancers motivated a second global survey on comprehensive biomarker testing in 2024. METHODS: The International Association for the Study of Lung Cancer convened a global multidisciplinary committee to develop the survey. We used a mixed methods framework, with qualitative focus groups and in-depth interviews informing the primarily quantitative survey. The survey was available in six languages. RESULTS: We received 1677 responses across 90 countries and 14 disciplines. Respondents believe that biomarker testing significantly affects outcomes (98.3%) and have a clear understanding of who should receive testing (91.2%). Nevertheless, only 63.4% and 29.4% ranked it highly important to perform comprehensive biomarker testing in late- and early-stage lung cancer, respectively. Many respondents (67%) estimated that more than half of individuals with lung cancer are biomarker tested in their country, up from 39% in the 2018 survey (p value < 0.0001). Nevertheless, 43% of the respondents sometimes or often treat patients before receiving biomarker results. The highest ranked barriers were cost (27.2%), time (13.9%), sample quality (13.8%), access (12.8%), and awareness (8.0%). We found that the health care system support for biomarker testing varied by country-level income. CONCLUSIONS: We found improvements in the perception of testing rates compared with that in 2018, but continued and substantial barriers exist. Future initiatives will use these data to target awareness, access, processes, and policy initiatives to improve comprehensive testing globally.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Smeltzer MP, King JC, Connolly C, et al. The 2024 International Association for the Study of Lung Cancer Global Survey on Biomarker Testing. J Thorac Oncol. 2025. PMID: 40706709. doi:10.1016/j.jtho.2025.07.114

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。